Stay updated on Cabozantinib vs Sunitinib in Variant Histology RCC Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib vs Sunitinib in Variant Histology RCC Clinical Trial page.

Latest updates to the Cabozantinib vs Sunitinib in Variant Histology RCC Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe webpage has undergone significant updates, including the addition of detailed classifications of renal cell carcinoma and the identification of key collaborators such as Exelixis and the National Cancer Institute. Additionally, the revision number has been updated to v2.15.0.SummaryDifference62%
- Check42 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4 and changed the date from 2025-03-25 to 2025-01-09.SummaryDifference0.3%
- Check49 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check85 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1.0%
- Check100 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to Cabozantinib vs Sunitinib in Variant Histology RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib vs Sunitinib in Variant Histology RCC Clinical Trial page.